05:06 AM EDT, 09/30/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said Monday that updated data from a phase 1 trial evaluating JNJ-1900 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma demonstrated "early efficacy signals" and a well-tolerated safety profile.

The company said JNJ-1900 was activated by radiation therapy and followed by anti-PD-1 immune checkpoint inhibitors in the trial and the updated data are from patients who are naive or resistant to prior anti-PD-1 therapy.

Survival data in anti-PD-1 resistant patients suggests that the treatment may overcome prior resistance to immune checkpoint inhibitors, according to Nanobiotix ( NBTX ).